Cardiovascular Health Research Unit, Seattle, WA IOM recommendations on drug safety: relevance for vaccines? Bruce M Psaty, MD, PhD.

Slides:

Advertisements

Similar presentations

The Drug Discovery Process

Advertisements

The Radioactive Drug Research Committee Approval Process for Tracer Use Anthony F. Shields, M.D., Ph.D. Karmanos Cancer Institute Wayne State University.

FDA REGULATION: EFFECT ON PAIN MANAGEMENT IN THE ED RICHARD R. ABOOD, R.Ph., J.D. Professor Pharmacy Practice University of the Pacific RICHARD R. ABOOD,

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

Special Topics in IND Regulation

Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.

1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Health Science/Research Policy Group II. Problem Statement Safety and effectiveness of prescription drugs in a real-world environment are uncertain because.

Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.

The Food and Drug Administration Amendments Act of 2007: Implications of the Drug Safety Provisions Carolyn D. Jones, J.D., MPh Director, Regulatory Policy.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Stefan Franzén Introduction to clinical trials.

Department of Health and Human Services Food and Drug Administration DMETS Evaluation of Proprietary Names Jerry Phillips, RPh Associate Director Office.

Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

From the Lab to Market Unit 3.04 Understanding Biotechnology research & Development.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

FDA Focus On Consumer Protection

Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.

An epidemiologic perspective on etoricoxib David J. Graham, MD, MPH Office of Surveillance and Epidemiology April 12, 2007.

Risk Management Strategy for the Pharma and Biotech Product Lifecycle : New Regulatory and Legal Focus and Approach Morgan, Lewis & Bockius, LLP August.

Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.

VIOXX ™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001 Lourdes Villalba, M.D. DAAODP, CDER, FDA.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

The New Drug Development Process (www. fda. gov/cder/handbook/develop

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Chapter 71 Data Ethics. Chapter 72 Thought Question 1 Many new treatments for rapidly lethal diseases offer very little or no benefit to patients. Thus,

FDAAA – Report on DTC Advertising Kristin Davis, J.D. Deputy Director, Division of Drug Marketing, Advertising, and Communications Office of Medical Policy,

Advisory Committee Presentation on Vioxx (Rofecoxib) Discussion on the meta analyses for cardiovascular risk assessment Qian Li, Sc. D.

FDA Office of Orphan Products Development

1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.

The pursuit of “the right things”: Lessons from Evidence Based Medicine 1.0 Paul Wallace MD The Permanente Federation

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Stakeholder Meeting on the Implementation of the Medical Device User Fee and Modernization Act of 2002 (MDUFMA) November 17, 2005 Diana Zuckerman, Ph.D.

Special Concerns Relating To Promotional Labeling And Advertising For Medical Devices.

What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.

1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.

Risk Management, Risk Communication, and Drug Safety: The U.S. Experience Geoffrey Levitt Chief Regulatory Counsel Wyeth August 23, 2007.

FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 BETTER APPROACHES TO MONITORING MEDICAL PRODUCT SAFETY ARE NEEDED.

Drug Regulation in Controversy: Vioxx November 10, 2004 Sandra L. Kweder, M.D. Deputy Director, Office of New Drugs Center for Drug Evaluation and Research.

Risk Assessment Public Meeting - 4/9/03 1 Premarketing Risk Assessment Robert J. Meyer, MD Director, ODE II / OND / CDER Chair of RA Working Group.

Clinical Trials.

FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.

Regulatory Updates Health Sciences Authority Singapore

U.S. FDA Center for Devices and Radiological Health Update

VIOXX WITHDRAWAL: Learning valuable lessons from rofecoxib

Clinical Trials — A Closer Look

Within Trial Decisions: Unblinding and Termination

FDA Guidance for Industry and FDA Staff Summary of Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”) Effective: December.

Combination products The paradigm shift

Speeding access to therapies

Beyond Academia.

Overview of FDA’s 2005 Risk Management Guidance

Pediatric Therapeutics Still working to get it right for kids

Regulatory Perspective of the Use of EHRs in RCTs

Presentation transcript:

Cardiovascular Health Research Unit, Seattle, WA IOM recommendations on drug safety: relevance for vaccines? Bruce M Psaty, MD, PhD

CHRU Drugs and vaccines: prevention DrugsVaccines PaymentAd hocVFC program Rx durationLongShort Rapid uptakeDTCAGuidelines Phase III standardSurrogatesClinical benefit PM safety eventsUncommonRare Injury compTort lawNo-fault system Orenstein WA. Health Affairs 2005; 24:

CHRU US drug-safety system Pharmaceutical industry lacks a symmetric interest in safety and efficacy Since 1960s, approval marks transition from evaluation to marketing With rapid approvals since 1992, current post-market system--AERS plus PM commitments--could hardly be weaker Steenburg C. Food Drug Law 2006; 61:

CHRU Guidance to assess safety For new drugs intended for long-term use in non-life threatening conditions –1500 subjects exposed –300 to 600 subjects for 6 months –100 subjects for 1 year Rofecoxib NDA as example –58 studies in 5771 patients –3629 received rofecoxib 1 day or more –752 received usual doses for 1 year Guidance ICH E1a, Villalba M. Review of Vioxx, 1999.

CHRU US post-market safety system FDA-based part of the system –AERS and some observational studies Industry-based part of the system –PM commitments and other studies 66% of med officers lack confidence that the “FDA adequately monitors the safety of prescription drugs … on the market” OIG Report. OEI March 2003.

CHRU Post-market commitments Agreed to by sponsors pre-approval For one sponsor, 7 of 11 PMCs identified within 3 weeks of approval Designed by sponsors, who often lack an imaginative interest in safety studies Reviewed by OND medical officers, who often don’t know what studies to request OIG report. FDA review process, March 2003.

CHRU Industry-funded studies MEDAL program with 24,913 subjects –Compared etoricoxib and diclofenac –Similar pain relief, GI and CV AEs Diclofenac as comparator –Best selling NSAID world-wide –COX2 selectivity similar to celecoxib –Compared with naproxen, 70% increase in vascular events Psaty BM. N Engl J Med 2007; 356:

CHRU Lifecycle approach On-going evaluation of safety and efficacy of drugs during their market life Systematic approach to identifying and translating safety signals into high- quality studies Pursuit and management of emerging knowledge about risks and benefits

CHRU IOM recommendations New funding, preferably from general revenues rather than user fees New authorities for the FDA –Labeling and post-market studies –New enforcement tools Black triangle and restricted direct to consumer advertising

CHRU IOM recommendations Leadership promoting a culture of safety Access to new tools and new data Integration of ODS/OSE in OND reviews and shared for post-market decisions Development and use of risk-benefit analyses

CHRU Some potential remedies Congressional legislation –Clinical trials registration (S467) –Grassley-Dodd bill (S468) –Kennedy-Enzi bill (S484) –PUDFA reauthorization in 2007 Wise drug use by physicians & patients –Suspend use of some drugs –Use well-studied drugs